Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

Researchers conducted an analysis of how NCCN guidelines for myeloma treatment are updated, offering suggestions for a more standardized process.

Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...